Bayesian adaptive designs in early phase clinical trials
Abstract
There are two practical challenges in the phase I clinical trial conduct: lack of transparency to physicians, and the late onset toxicity. In my dissertation, Bayesian approaches are used to address these two problems in clinical trial designs. The proposed simple optimal designs cast the dose finding problem as a decision making process for dose escalation and deescalation. The proposed designs minimize the incorrect decision error rate to find the maximum tolerated dose (MTD). For the late onset toxicity problem, a Bayesian adaptive dose-finding design for drug combination is proposed. The dose-toxicity relationship is modeled using the Finney model. The unobserved delayed toxicity outcomes are treated as missing data and Bayesian data augment is employed to handle the resulting missing data. Extensive simulation studies have been conducted to examine the operating characteristics of the proposed designs and demonstrated the designs' good performances in various practical scenarios.
Subject Area
Biostatistics
Recommended Citation
Liu, Suyu, "Bayesian adaptive designs in early phase clinical trials" (2012). Texas Medical Center Dissertations (via ProQuest). AAI3527694.
https://digitalcommons.library.tmc.edu/dissertations/AAI3527694